Table 2 Univariate and multivariate regression analysis to identify predictors for hepatotoxicity related to erlotinib administration
From: Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study
Characteristics | Unadjusted OR (95% CI) | Adjusted OR (95% CI) | Attributable risk |
|---|---|---|---|
Male | 0.826 (0.475–1.437) | 0.987 (0.516–1.886) | |
Age ≥ 65 | 1.316 (0.760–2.280) | 1.257 (0.718–2.203) | |
BSA ≥ 1.6a | 0.730 (0.422–1.263) | 0.728 (0.383–1.385) | |
Liver metastasis | 1.717 (0.934–3.156) | 1.862 (1.001–3.465)* | 46.3 |
CYP3A4 Inducer | 2.401 (0.936–6.162) | 2.660 (1.013–6.982)* | 62.4 |